Sarilumab not checked
Sanofi · SAR153191 · REGN88
FollowEvery change as it happens, and a Monday email
Trials
8 active
15 in total · 7 in the EU
What this is
- How it works
- Blocks interleukin-6, a signal that drives inflammation.Interleukin-6 Receptor Antagonist FDA class
- How it’s given
- “Pharmaceutical form: Solution for injection - Route of administration: Subcutaneous”In the company’s words, NCT07286214 on ClinicalTrials.gov
- Main trialPhase 3
- “This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 3, 3-arm study to assess whether treatment with sarilumab at either 150 mg q2w (once every two weeks) or at 200 mg q2w, each given with a 52-week prednisone taper, is superior to placebo given with a 52-week prednisone taper in participants with early polymyalgia rheumatica (PMR) and to determine the safety and tolerability of the sarilumab regimens. The study will consist of the following visits: Visit 1 (D-42 to D-1): Screening, Visit 2 (D1): Baseline, randomization, first study drug administration, Visit 3 to…”In the company’s words, NCT07286214 on ClinicalTrials.gov
- Other names
- Kevzara · SAR153191 · REGN88
Other drugs for Polymyalgia Rheumatica
- SecukinumabNovartis Pharmaceuticals · Phase 3
- OlokizumabR-Pharm International, LLC · Phase 3
Coming up3
- 1 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
- 26 Oct 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 4 Jun 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 4 Jun 2029 | Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica | |
| Phase 2Recruiting | 1 Mar 2028 | A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) | |
| Phase 1/2Recruiting | 26 Oct 2028 | Phase 1b/2 Study of IV Sarilumab in Adult With RA | |
| Phase 4Completed | 31 Jul 2019 | Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis | |
| Phase 3Completed | 20 Jan 2016 | Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH) | |
| Phase 3Completed | 31 Jul 2020 | Sarilumab COVID-19 | |
| Phase 3Terminated | 24 Nov 2020 | Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA | |
| Phase 3Completed | 31 Dec 2020 | Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND) | |
| Phase 3Terminated | 19 May 2021 | Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica | |
| Phase 2Completed | 8 Apr 2022 | An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) | |
| Phase 4Authorised | not given | The 3TR Molecular Pathobiology-Driven Precision Therapy in RA (3TR Precis-The-RA) study | |
| Phase 4Authorised | not given | A 24 weeks proof of concept study to evaluate the clinical, MRI and synovial tissue benefit of Sarilumab in active RA patients despite TNF agents | |
| Phase 3/4Authorised | not given | RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial) | |
| Phase 4Authorised | not given | Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial | |
| Phase 4Authorised | not given | Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026